Utility Of Citogenex Administration In Patients With Colon-Rectal Cancer
CITOGENEX is a dietary supplement of insoluble polysaccharides, of Lactobacillus Casei
(specific type) and of Bifidobacterium Lactis (specific type). These subspecies of
probiotics bacteria have been shown to be effective in improving the immunity. Several
trials are currently underway, in order to evaluate the effects of probiotics as potential
novel therapies in addition to traditional therapeutic approaches. Although probiotics do
not play an anti-tumor action per se, these agents may significantly contribute to decrease
the typical side effects due to traditional anti-tumor treatments, such as gastrointestinal
symptoms, immunity deficit, as well as the alterations in the gut lymphoid tissue.
It is therefore expected that CITOGENEX may have several significant beneficial effects in
patients under anti-tumor treatments. In order to test this hypothesis, we will perform a
randomized, single-blind, two-arms, prospective study in patients with colon-rectal cancer.
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
All cause mortality
2 years
Yes
Giovanni Tomasello, MD
Study Director
University of Palermo
Italy: National Monitoring Centre for Clinical Trials - Ministry of Health
CITOGENEX CRC
NCT01477866
January 2012
December 2014
Name | Location |
---|